Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02354612
Title An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy
Recruitment No longer available
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Tracon Pharmaceuticals Inc.

Advanced Solid Tumor


Axitinib + Carotuximab

Carotuximab + Pazopanib

Capecitabine + Carotuximab


Bevacizumab + Carotuximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.